Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the trial had “evidentiary and legal errors,” and the company will appeal the verdict.
The post Takeda Vows Appeal of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case appeared first on MedCity News.
